Pipeline

By focusing on the most common and shared frameshift mutations across hereditary and sporadic MSI cancers Hubro Bioscience has established a proprietary frameshift mutation detection technology platform. The core target frameshift mutations of technology platform cover frameshift mutation in TGFβR2, ASTE1, TAF1B and ACVR2A. Additional targets are being explored. 

The frameshift targeted technology platform provides a solid basis for the development of diagnostic tests useful for MSI-cancer risk surveillance potentially allowing early treatment and improved outcome of treatment.